- Policy
- AZ seeks reimb of its triple inhaled therapy for COPD
- by Lee, Tak-Sun Aug 10, 2022 05:52am
- New triple drug inhaled therapies for COPD (Chronic Obstructive Pulmonary Disease) are working to receive insurance reimbursement in Korea. After GSK cut the first tape to reimbursement with its ‘Trelegy Elipta’ in June last year, AstraZeneca has also applied for the reimbursement of its ‘Breztri Aerosphere,’ which was approved in Novemb
- Policy
- When replacing Spinraza→Zolgensma, it should be injected
- by Lee, Hye-Kyung Aug 10, 2022 05:52am
- If SMA patients who were administering Biogen's Spinraza want to be replaced with Zolgensma, an ultra-high-priced one-shot treatment from Novartis Korea, they should have a minimum administration interval of 4 weeks. Regardless of whether or not benefit of Zolgensma is applied, replacement administration to other treatments after Zolgensma
- Policy
- Administration of Evusheld begins to prevent COVID-19
- by Kim, Jung-Ju Aug 9, 2022 05:57am
- From today (8th), the quarantine authorities will administer Evusheld, an antibody injection for prevention, for severely immunocompromised patients. The COVID-19 Vaccination Response Promotion Team (Director Baek Kyung-ran) announced today (the 8th) that it will start taking Evuseld to prevent COVID-19 among immunocompromised people. Evuseld
- Policy
- Oxiracetam’s next...ordeal of brain function enhancers
- by Lee, Tak-Sun Aug 9, 2022 05:56am
- It’s a time of ordeal for brain function enhancers. In addition to choline alfoscerate, whose scope of use has been reduced through reimbursement reevaluations, acetyl-L-carnitine failed to demonstrate its efficacy during clinical reevaluations. As a result, acetyl-L-carnitine is expected to completely disappear from the prescrip
- Policy
- It's hard to prescribe oral medicine for COVID-19
- by Kim, Jung-Ju Aug 9, 2022 05:56am
- Amid the remarkable re-proliferation of COVID-19, the newly proposed National Infectious Disease Crisis Response Advisory Committee advised medical staff to create detailed guidelines for prescriptions in consideration of difficulties in the dispensing process. The National Advisory Committee on Infectious Disease Crisis Response (Chairman
- Policy
- MFDS beings rolling review of Pfizer’s multivalent vaccine
- by Lee, Hye-Kyung Aug 8, 2022 06:09am
- The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) announced that it had started a rolling review on the clinical trial data that Pfizer Korea submitted on the 5th for its COVID-19 vaccine ‘Comirnaty2 Inj. 0.1mg/mL.' Comirnaty2 Inj. 0.1mg/mL. is a multivalent mRNA vaccine that presents antigens for both the original COVID-19 v
- Policy
- 500 billion won in K-Bio and Vaccine Fund was created
- by Kim, Jung-Ju Aug 8, 2022 06:09am
- The government has finalized a plan to create a K-Bio and Vaccine Fund" worth a total of 500 billion won this year and has started selecting operators. In the future, the government plans to expand the scale to around 1 trillion won. The MOHW (first vice minister Cho Kyu-hong) announced on the 4th that it will report and confirm the plan to c
- Policy
- Supply of Children's Tylenol suspension will be normalized
- by Lee, Tak-Sun Aug 7, 2022 11:30pm
- The product license was withdrawn due to the suspension of the operation of the Jansen Hyangnam plant in Korea, but the new product re-licensed due to technology transfer will be listed as starting in August. This includes child Tylenol suspension, and attention is being paid to whether supply and demand will be normalized with new benefits,
- Policy
- Security elaboration/ ultra-high-priced new drug coverage
- by Kim, Jung-Ju Aug 5, 2022 06:04am
- In order to strengthen accessibility to new drug patients, the government has steadily increased coverage by opening a benefit gateway. However, due to the development of innovative new drugs, limited funding of health insurance is a problem to catch up with the ultra-high price trend of anticancer drugs and rare disease treatments. The chall
- Policy
- MOHW reluctant to CVS's request to expand SRADs
- by kang, hae-kyung Aug 5, 2022 06:04am
- The Ministry of Health and Welfare expressed disapproval over the convenience store industry's request that the scope of Safe and Readily Available Drugs (SRADs) should be expanded to antacids and burn ointments for sale at convenience stores. The MOHW explained that the SRAD system is a unique exception made from the healthcare system’s
